Navigation Links
Ellex Commences Direct Sales in Germany

ADELAIDE, Australia, Sept. 10 /PRNewswire/ -- Ellex Medical Lasers Limited (ASX: ELX) today announced another step in expanding its global reach with the establishment of a direct sales channel in Germany -- Ellex Deutschland GmbH.

To be formally launched at the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Berlin, 13-16 September 2008, Ellex Deutschland GmbH will focus initially on sales of Ellex laser products. Ellex's distribution partner for the Eye Cubed ultrasound product in Germany, M+C GmbH, will provide administration and logistical support for the new operations, allowing Ellex to establish a strong market position with minimal investment and reduced risk.

M+C have been active in the ophthalmic market for 20 years and have distributed the Eye Cubed since 1990. Their excellent reputation and strong sales and marketing network will be a significant benefit in establishing Ellex quickly in the German market. The partnership between Ellex and M+C will enable both companies to leverage common marketing channels and contacts. Plans include joint exhibits at German trade shows, promotional campaigns and educational workshops.

With over 8,000 ophthalmologists, Germany is one of the largest ophthalmic markets in the world. "The German market has significant potential and we look forward to working directly with ophthalmic surgeons throughout the region to demonstrate the quality of our products and our commitment to service. We are fortunate to have attracted experienced sales and service staff, and have the benefit of partnering with M+C, who have been our leading Eye Cubed distributor for many years," commented CEO Mr. Kevin McGuinness.

The first sales from the German operation are expected in September 2008. Ellex Deutschland GmbH will participate in its first official exhibition during the 2008 congress of the Deutsche Ophthalmologische Gesellschaft (DOG), which takes place immediately following the ESCRS in Berlin. The DOG is attended by more than 3,000 ophthalmologists and staff.


Ellex Medical Lasers Limited (ASX: ELX) designs, manufactures and markets a complete line of lasers and diagnostic ultrasound systems used by ophthalmologists to diagnose and treat eye diseases. With more than 14,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan and Australia, and a network of distribution partners in more than 100 countries. In December 2006 Ellex acquired Innovative Imaging, a leading provider of diagnostic ultrasound devices for ophthalmology, initiating the expansion of its product line beyond lasers. Ellex maintains a strong emphasis on intellectual property and research into new and better treatments to manage and treat the leading causes of blindness.

For additional information about Ellex and its products, please visit

SOURCE Ellex Medical Lasers Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
2. MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
3. Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share
4. uKarma Corporation Commences International Distribution Agreement With Northern Response for its Xflowsion DVD Series
5. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
6. China Sky One Medical, Inc. Commences Trading on the American Stock Exchange
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
9. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
10. Cytopia Commences Phase II Cancer Drug Study
11. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
Post Your Comments:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: